How Supplements Are Regulated and Tested: What to Know Before You Buy

No agency confirms that a supplement works, contains what its label claims, or matches the dose that was studied — here is how to evaluate a product yourself.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not to replace medical care.

In brief: When you buy a supplement in the United States, no government agency has confirmed that it works, that it contains what its label claims, or that the dose inside reflects the dose used in clinical trials. That is not a regulatory failure but the legal structure: supplements are sold as food, not drugs, and the burden of evaluation falls to the buyer. Article 1 covered the first question of any supplement decision — does the ingredient have real evidence; this article covers the second — does the product in your hand actually deliver what that evidence tested. It maps how supplements are regulated, what can be in the bottle, what third-party certification does and doesn’t verify, and a five-step framework that turns both questions into a single decision.

Introduction

Article 1 covered the first question of every supplement decision: does the evidence exist? This article covers the second: does the product you are holding actually deliver what that evidence tested — the right dose, the right chemical form, independently verified quality? Both must be answered before any purchase makes sense.

A compound can have genuine clinical evidence and still reach you in a product with the wrong dose, the wrong chemical form, or an ingredient not on the label at all. Equally, a product can be exactly what it claims and still contain an ingredient never shown to prevent a cardiovascular event. Neither question answers the other, and in a marketplace where no independent authority verifies either one before a product reaches the shelf, the work of answering them falls to the buyer.

That is not a cynical position; it is the legal structure of the supplement industry in the United States. This is not an argument that supplements are inherently dangerous or that the marketplace is uniformly compromised — many products are well made, and many companies operate responsibly. But the system does not distinguish, at the point of sale, between a product that deserves confidence and one that does not. So before buying any cardiovascular supplement, three things have to be confirmed independently: that the ingredient has real clinical evidence (Article 1’s Ten Questions), that the product matches the dose and chemical form that was studied, and that an independent organization such as USP, NSF, or ConsumerLab has verified what is actually in the bottle.

Why Supplements Are Different from Drugs

Prescription drugs must demonstrate both safety and efficacy before reaching the market. Development typically takes a decade or more of clinical testing, culminating in FDA review, and if the evidence is insufficient, the drug is not approved.

Supplements operate under entirely different rules. Under U.S. law, dietary supplements are classified as food rather than drugs. (1) They do not require FDA approval before sale, and they do not need to prove they work. A company can formulate a supplement and have it on shelves within weeks, with no agency having reviewed whether it works or whether it contains what the label claims. This is not an oversight or a loophole; it is how the law was written. The FDA can act against supplements that are dangerous or fraudulently labeled, but only after they are already being sold and a problem has been identified. The burden of proof is reversed: rather than requiring companies to demonstrate safety and efficacy before sale, the government must demonstrate harm after the fact. (1)

Put plainly: prescription drugs generally require pre-market evidence of safety and effectiveness; dietary supplements generally do not.

What the structure produces: ephedra

The clearest illustration of what this structure can produce is ephedra. Ephedra (sometimes labeled ma huang) contains ephedrine alkaloids — stimulants that act on the cardiovascular and central nervous systems. Through the 1990s and early 2000s, ephedra supplements were widely marketed for weight loss, energy, and athletic performance, and under the rules just described, no agency reviewed their cardiovascular safety before they reached shelves.

What followed was a sustained pattern of harm. An FDA-commissioned review of 140 adverse-event reports linked to ephedra found that nearly half involved cardiovascular symptoms — heart attack, stroke, and sudden death among them — often in young, otherwise healthy adults. (10) Reports tied to ephedra eventually numbered in the thousands, and several high-profile cardiovascular deaths in the early 2000s drew national attention to a problem that medical journals had been documenting for years. In 2004 the FDA banned dietary supplements containing ephedrine alkaloids — the first ingredient ever removed from the U.S. supplement market under the law that still governs the industry. (1,12) Afterward, poison-control reports of serious ephedra effects dropped by more than 98%. (11)

Ephedra is an extreme case, and most supplements never approach that level of harm. But the structural feature it exposed — no mandatory pre-market verification — applies to every product on the shelf, not just the few eventually pulled. Which raises the practical question: beyond outright danger, what else can go wrong with a product no one has independently checked?

What Can Go Wrong With the Product

Independent testing and regulatory surveillance have documented a range of quality failures, falling into three categories, each with real-world data behind it.

Wrong amount

The amount of active ingredient can differ substantially from what the label states. Melatonin has become the model for this problem because it is widely used and straightforward to measure. In one widely cited analysis of 31 commercial products from 16 brands, actual melatonin content ranged from 83% below to 478% above the labeled amount; lot-to-lot variability within a single product reached 465%; more than 71% of products failed to meet their label within a 10% margin; and 26% contained unlabeled serotonin, a neurohormone with significant pharmacologic activity. (2) A later FDA analysis of 110 melatonin products marketed for children found content ranging from 0% to 667% of the labeled amount. (3)

Cardiovascular supplements have not been studied at this scale, but the regulatory structure that produced these failures applies identically to every category — there is no separate manufacturing standard or extra oversight for a CoQ10 capsule or a magnesium tablet than for a melatonin gummy. (1) The clinical implication runs both ways: underdosing means a person is not getting the amount that trials studied, so the evidence does not apply to what is actually being taken; overdosing creates its own risks, especially with compounds that have dose-dependent effects on blood pressure, clotting, or drug metabolism.

Undeclared pharmaceutical drugs

A more serious problem is products containing substances not listed on the label at all. An analysis of the FDA’s Tainted Products database identified 776 dietary supplements between 2007 and 2016 that contained undeclared pharmaceutical drugs, from 146 different companies. (4) These were not fringe products; they were actively marketed and sold, and more than 20% contained more than one undeclared drug. (4) A follow-up through 2021 put the cumulative total at 1,068 unique adulterated products — a single product sometimes containing as many as five active pharmaceutical ingredients — and found that products are sometimes reformulated with new undeclared drugs and kept on sale even after FDA warnings. (5)

For cardiovascular patients, the risk is direct. The most common adulterant in weight-loss products was sibutramine (4), a drug withdrawn from the U.S. market for raising the risk of heart attack and stroke; the most common in sexual-enhancement products was sildenafil, the active ingredient in Viagra, which can cause a severe, sometimes fatal drop in blood pressure when combined with the nitrates commonly used for chest pain and heart failure. A supplement that looks entirely unrelated to the heart may contain an ingredient with direct cardiac effects that neither the patient nor the clinician knows is present — a documented, ongoing pattern: more than a thousand such products were identified between 2007 and 2021. (5)

Wrong chemical form

Many compounds exist in several chemical forms with very different bioavailability — the proportion that actually reaches circulation. Magnesium oxide is absorbed far less well than magnesium citrate, though both are labeled simply “magnesium.” (6) The same trap runs across the supplement aisle: CoQ10 is sold as both ubiquinone and ubiquinol, two forms with different absorption; “omega-3” stretches from mixed EPA/DHA fish oil to the purified EPA studied in cardiovascular outcome trials. In each case a single label word stands in for forms the body handles differently. Trials study a defined form at a defined dose, and evidence for one does not transfer to another. If the trial used citrate and the bottle contains oxide, the research does not support what is inside, even when the milligrams on the label match.

Across all three failure modes, the pattern is the same: what the label says and what enters the body are not always the same thing.

Third-Party Testing: What It Verifies and What It Doesn’t

In a marketplace without mandatory pre-market testing, independent certification is the most reliable quality signal available — provided you understand precisely what it confirms. Three organizations conduct widely recognized supplement certification in the United States: USP (United States Pharmacopeia), NSF International, and ConsumerLab. Each tests finished products for label accuracy, potency, purity from contaminants, and dissolution — whether the capsule or tablet actually breaks down and releases its contents in the body. NSF’s Certified for Sport program additionally screens for substances banned in major sports. (7)

A verified seal from one of these organizations means an independent laboratory has confirmed the product contains what the label claims, at the stated dose, without harmful contaminants, in a form that dissolves properly. (7) What it does not tell you is whether the compound itself works for your cardiovascular goals: a product can be exactly what its label claims and still contain an ingredient with no meaningful cardiovascular evidence behind it.

Two limitations matter especially. First, these programs are voluntary — companies apply and pay for certification, and most supplements have never been tested by any of them. Second, a label reading “third-party tested” or “quality verified” without naming a certifier is not the same as USP Verified, NSF Certified, or ConsumerLab-tested; those vague phrases have no legal definition and require no independent verification. What counts is a seal from a named, recognized certifier, confirmed on that organization’s own website, since certifications can lapse or be withdrawn. Certification, in short, verifies what is in the bottle; it does not verify that what is in the bottle does anything for your heart. A flawlessly manufactured supplement can still be ineffective, and an effective ingredient can still arrive in a poorly made product — quality and effectiveness are independent, and a product can fail on either one.

What Marketing Claims Actually Mean

Even when a product contains exactly what it claims, the language on the label can mislead, because the phrases that sound most authoritative are often the ones with the least evidence behind them. Most are legally permitted marketing language rather than statements of clinical evidence, and the regulatory basis for that is the structure/function claim rules. (1,8)

As Article 1 examined, “clinically studied” is a statement about research activity, not proof — it can rest on a single small pilot trial, animal data, a formulation different from the product, or a manufacturer-funded result never independently replicated. None of the phrases above require demonstrated cardiovascular benefit.

There is one real exception. A narrow category of claims has been formally reviewed by the FDA under the significant-scientific-agreement standard, a meaningfully higher bar than structure/function language. In cardiovascular health, two are authorized: plant sterols and stanols for reducing coronary heart disease risk, and soluble fiber from certain sources for the same indication (examined in Articles 6 and 7). (9) When you encounter FDA-authorized language, it signals something real. Everything else leaves the evidence for you to find.

Supplements and Cardiovascular Medications

Supplements can interact with cardiovascular medications in clinically significant ways — altering drug levels, amplifying or opposing drug effects, or introducing cardiovascular risks neither patient nor clinician anticipates. The interactions that matter most — St. John’s wort with statins and calcium channel blockers, vitamin K with warfarin, high-dose omega-3s with anticoagulants — are covered in Article 20, which is dedicated to supplement-drug interactions in cardiovascular care.

One practical point before that article: supplements are often not thought of as medications, so they go undisclosed more often than they should. For anyone on cardiovascular medication, telling the prescribing physician and pharmacist about every supplement is not optional caution; it is sound clinical practice. And bring the actual label to that conversation, not a description — the ingredient, dose, and form visible. Clinicians cannot evaluate what they cannot see. If you take cardiovascular medications, read Article 20 before starting any supplement.

Before You Buy: A Five-Step Framework

These five steps apply both questions — evidence and product — in sequence. Working through them in order separates supplements worth serious consideration from those that have not yet earned it.

Step 1 — Does the ingredient have real clinical evidence? This is the first of the two questions, and the rest of this series answers it for each major cardiovascular supplement. If the answer is no, the case for taking it rests on biology, not proof, and the remaining steps do not change that.

Step 2 — Does this product match that evidence? Confirm three things: the dose matches what the trials used, the chemical form matches what was studied, and the product has been independently verified by USP, NSF, or ConsumerLab. (7) If any of the three does not align, the clinical evidence does not apply to what you are buying, even if the ingredient itself has genuine data behind it.

Step 3 — Is this displacing something with stronger evidence? Supplements should not delay or substitute for therapies with demonstrated outcome data. Considering a supplement instead of a medication your physician recommended, or as a reason to defer a clinical conversation, is the wrong use of supplement evidence regardless of how compelling the marketing sounds. This is the step most often skipped, and the one with the most serious consequences.

Step 4 — Is the expected benefit meaningful relative to cost? Even when evidence exists, the benefit is often modest — most cardiovascular supplements, where they work at all, move intermediate markers rather than delivering the large risk reductions proven medications do. A supplement at $30 to $50 a month, taken for years, is a real expense that deserves to be weighed honestly against the strength of the evidence and the likely size of the benefit.

Step 5 — Are there interaction concerns? If you take cardiovascular medications, discuss any new supplement with your physician or pharmacist before starting it. Article 20 covers the documented interactions most relevant to cardiovascular patients.

One caution applies wherever you buy: online marketplaces can mix legitimate products with expired, counterfeit, imported, or reformulated versions. Buying directly from the manufacturer or a verified retailer reduces, though does not eliminate, this risk.

The Framework in Action

Here is what those five steps look like applied to a real decision — one that plays out in millions of households every year.

A person with elevated blood pressure reads that magnesium “supports healthy blood pressure” and considers adding a supplement.

The evidence is real, but conditional. Magnesium supplementation has shown blood-pressure effects in randomized trials, larger in people who are deficient and smaller or absent in those with adequate levels. (Article 10 examines this in detail.) The threshold question is whether this person is actually deficient — and they do not know.

The product does not match what was tested. The bottle on the shelf is magnesium oxide, which delivers far less to the bloodstream than the better-absorbed forms used in many trials. (6) Regardless of how the milligrams compare on paper, the evidence does not apply to what is in this bottle.

There is a displacement problem. This person is already on an antihypertensive. Adding a supplement with blood-pressure effects without disclosing it introduces a variable their physician cannot account for.

The cost is certain; the benefit is not. The supplement runs $40 a month. Even if magnesium helped here — uncertain without knowing this person’s levels — the likely benefit alongside an established antihypertensive is small and conditional. The cost is real; the expected benefit is not.

The conversation belongs with the physician, who can check a magnesium level. If it is low, correcting it through diet or a better-formulated product is a reasonable discussion. If it is normal, the case for supplementing is weak.

That is the framework working as intended — not to justify a purchase, but to reach an honest answer. Most people who buy that product take a low-bioavailability form, at a dose that may not match what trials used, for a deficiency they may not have. The label said nothing false. It just answered none of the questions that matter.

Two Products, Same Label, Different Realities

To see how the product question plays out, consider two products both legally marketed as “omega-3 supplements” that share almost nothing else.

Product A is a typical mass-market fish-oil capsule: “Omega-3 fish oil, 1,000 mg per softgel,” promoted as “supports heart health.” There is no third-party seal, the EPA-to-DHA ratio is unspecified, and the chemical form (ethyl ester versus triglyceride) is not disclosed. Total EPA plus DHA is roughly 300 mg per softgel, at about $10 a month.

Product B is a pharmaceutical-grade prescription product: icosapent ethyl — the purified EPA tested in the REDUCE-IT trial — at 1 gram per capsule, taken as 4 grams daily, FDA-approved to reduce cardiovascular events in a specific population (elevated triglycerides on statin therapy, with established cardiovascular disease or diabetes plus risk factors). (13) Cost varies by insurance; full retail is far higher than Product A.

Both contain “omega-3 fatty acids.” On regulatory category, manufacturing standard, dose, chemical form, evidence base, and FDA status, they share almost nothing. Product A has no large cardiovascular outcome trial in the population buying it; Product B has a defined patient group in which the evidence applies. Article 4 covers the omega-3 evidence. The single word “omega-3” is doing an enormous amount of work and concealing the difference — which is exactly the product question Article 1 raised as Question 10.

The same pattern repeats across categories — two products labeled “soluble fiber,” for instance, can differ in the viscosity that determines whether the LDL-lowering mechanism engages at all. The label is the start of the question, not the answer.

The Bottom Line

The supplement marketplace is not built to answer the two questions this article is organized around, and it is not required to. (1) No agency confirms that what is on the shelf contains what it claims, in the form that was studied, at the dose that showed an effect — so a product with genuine evidence behind it and one with none are indistinguishable at the point of sale: same confident label, same claims, same price. That is the legal structure, not an enforcement gap.

The consequences are concrete. More than a thousand commercially available supplements have been found to contain undeclared pharmaceutical drugs (5); melatonin products have tested at nearly six times their labeled dose (2); and the wrong chemical form can render even a correctly dosed product clinically meaningless. (6) None of it is visible on the label. The result of skipping the two questions is not just wasted money — it is a patient on a cardiac medication unknowingly adding an undeclared drug interaction, or managing a condition with a product that delivers a fraction of the studied dose, with no way of knowing either.

Article 1 asked whether the ingredient works; this article asks whether the product on the shelf is what was studied. The marketplace answers neither for you. The label says what the manufacturer wants you to believe, verification confirms what is actually in the bottle, and the trial evidence determines whether what is in the bottle does anything — three different questions, three different sources, and the consumer is the only one who connects them.

Article 3 turns to the biology underlying common supplement claims — oxidative stress, inflammation, endothelial function, lipid metabolism, and the other pathways marketing reliably borrows from — so that a cited mechanism becomes something you can translate rather than something that simply persuades.

Key Terms

Adulterated supplement: A dietary supplement found to contain undeclared substances, most often pharmaceutical drugs, not listed on the label. The FDA’s Tainted Products Database tracks these; more than 1,000 unique products were identified between 2007 and 2021.

Bioavailability: The proportion of a compound that reaches circulation and becomes available for biological activity. Different chemical forms of the same ingredient can differ substantially, which is why formulation matters as much as labeled dose.

DSHEA (Dietary Supplement Health and Education Act): The 1994 federal law establishing dietary supplements as food rather than drugs, removing any requirement to demonstrate safety and efficacy before sale. The legal foundation of the U.S. supplement marketplace.

FDA-authorized health claim: A claim category in which the FDA has reviewed the evidence and approved specific language, requiring significant scientific agreement. Meaningfully higher than a structure/function claim, and rare in the supplement marketplace.

Structure/function claim: Marketing language such as “supports heart health,” legally permitted without clinical proof. Does not require demonstrating that a product prevents or treats any condition.

Third-party certification: Independent laboratory verification that a product contains what its label states, at the claimed potency, without harmful contaminants, in a form that dissolves properly. Recognized programs include USP, NSF, and ConsumerLab. Does not verify that the ingredient is clinically effective.

References

1. Dietary Supplement Health and Education Act of 1994. Public Law 103-417. 103rd Congress.
2. Erland LAE, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–281.
3. Pawar RS, Coppin JP, Khanna S, Parker CH. A survey of melatonin in dietary supplement products sold in the United States. Drug Test Anal. 2025;17(8):1176–1185.
4. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open. 2018;1(6):e183337.
5. White CM. Continued risk of dietary supplements adulterated with approved and unapproved drugs: assessment of the US Food and Drug Administration’s Tainted Supplements Database 2007 through 2021. J Clin Pharmacol. 2022;62(8):928–934.
6. Walker AF, Marakis G, Christie S, Byng M. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnes Res. 2003;16(3):183–191.
7. Akabas SR, Vannice G, Atwater JB, Cooperman T, Cotter R, Thomas L. Quality certification programs for dietary supplements. J Acad Nutr Diet. 2016;116(9):1370–1379.
8. US Food and Drug Administration. Structure/Function Claims. Silver Spring, MD: FDA; 2022.
9. US Food and Drug Administration. Authorized Health Claims That Meet the Significant Scientific Agreement Standard. Silver Spring, MD: FDA; 2023.
10. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343(25):1833–1838.
11. Zell-Kanter M, Quigley MA, Leikin JB. Reduction in ephedra poisonings after FDA ban. N Engl J Med. 2015;372(22):2172–2174.
12. US Food and Drug Administration. Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk. Federal Register. February 11, 2004;69(28):6788–6854. Effective April 12, 2004.
13. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.

HeartBuddi • Your heart. Own it.